Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?

Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?

Source: 
Endpoints
snippet: 

As if Biogen’s aducanumab isn’t controversial enough, the researchers at drug pricing watchdog ICER have drawn up the contours of a new debate: If the therapy does get approved for Alzheimer’s by June, what price should it command?